Mucosolvan (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucosolvan, is a mucolytic presented as a standard inhalation formulation for inhalation use. It reduces mucus viscosity and facilitates clearance in patients with acute or chronic bronchitis, COPD exacerbations, and productive upper respiratory infections.

GNH USA supplies Mucosolvan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mucosolvan is used as a mucolytic agent to improve clearance of respiratory secretions in several bronchial conditions. - Acute bronchitis: helps loosen and clear mucus, reducing cough duration. - Chronic bronchitis: facilitates sputum expectoration, improving breathing comfort. - COPD exacerbations: reduces mucus thickness, aiding airway patency during flare‑ups. - Upper respiratory tract infections with productive cough: promotes clearance of secretions, alleviating cough.

Adverse reactions to inhaled ambroxol are generally mild, but some patients may experience more serious events. Common Side Effects: - Taste alteration: transient bitter or metallic taste. - Throat irritation: mild soreness after inhalation. - Cough increase: temporary worsening of cough. - Nausea: mild stomach discomfort. Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or breathing difficulty. - Bronchospasm: sudden airway tightening causing shortness of breath. - Angioedema: swelling of lips, tongue, or face.

When using Mucosolvan, consider the following precautions to ensure safe therapy. - Assess renal function: adjust use in severe renal impairment. - Monitor for hypersensitivity: discontinue if allergic signs appear. - Use with caution in asthma: may provoke bronchospasm in susceptible individuals. - Avoid in patients with known hypersensitivity to ambroxol or excipients. - Do not exceed recommended duration: prolonged use may lead to irritation. - Store below 25°C: keep in original container, protect from moisture and light.

Mucosolvan may interact with other medicines; awareness of the interaction level helps guide monitoring. Major Interactions (Avoid): - Concomitant use with other mucolytics: may increase risk of gastrointestinal irritation. - Combination with strong bronchodilators in asthmatic patients: may precipitate bronchospasm. Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may affect ambroxol metabolism. - Anticoagulants (e.g., warfarin): potential increase in bleeding tendency. - Anticholinergic agents: may reduce secretions, counteracting mucolytic effect.